David Helekal (University of Warwick, UK) and colleagues have published a new model to estimate AMR fitness cost and benefit. They found that two unrelated Neisseria gonorrhoeae lineages resistant to fluoroquinolones shared similar epidemic dynamics and resistance parameters.